Is deep transcranial magnetic stimulation (deep TMS) approved for the treatment of bipolar depression?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Deep TMS is NOT FDA-approved for bipolar depression

Deep transcranial magnetic stimulation (deep TMS) does not have FDA approval specifically for bipolar depression, and current evidence does not support its routine use for this indication. While deep TMS has been studied in bipolar depression research settings, the evidence remains insufficient and conflicting 1.

Current FDA Approval Status

Deep TMS lacks regulatory approval for bipolar depression. The available guidelines explicitly distinguish bipolar depression from unipolar major depressive disorder in treatment recommendations. Consensus guidelines specifically recommend that bipolar depression should be excluded from treatment-resistant depression (TRD) definitions and clinical trials, as it is part of bipolar disorder rather than major depressive disorder 2.

Evidence Quality and Limitations

A 2026 systematic review and meta-analysis of TMS for bipolar depression found 1:

  • Small overall antidepressant effect (SMD = -0.34) compared to sham
  • 88.2% of individual trials failed to show superiority over sham at the individual study level
  • Effects were not consistently confirmed in sensitivity analyses by treatment type, stimulation site, or treatment resistance
  • Most studies had small sample sizes (mean N = 15.4 per group)
  • 65% of studies had "some concerns" regarding risk of bias

While one open-label pilot study showed encouraging response rates (87.1%) and remission rates (74.2%) with high-frequency left-sided TMS in 31 patients with bipolar depression 3, this was uncontrolled and cannot establish efficacy.

Critical Clinical Considerations

If considering TMS for bipolar depression off-label, the following are mandatory:

  • Concurrent mood stabilizer treatment is essential - all patients in the pilot study were treated with mood stabilizers 3
  • Lithium co-treatment was associated with higher depression scores (worse outcomes) 3
  • Lamotrigine co-treatment was associated with lower depression scores (better outcomes) 3
  • Monitor closely for treatment-emergent mania or hypomania
  • No seizures or serious adverse events have been reported in bipolar depression studies 1

Approved Alternatives

For bipolar depression, FDA-approved pharmacological options include 4:

  • Olanzapine-fluoxetine combination (approved for bipolar depression in adults)
  • Lamotrigine (approved for maintenance therapy in adults)
  • Quetiapine (approved for acute bipolar depression)

The evidence base for these medications, while imperfect, substantially exceeds that for deep TMS in bipolar depression.

Bottom Line

Deep TMS remains an investigational treatment for bipolar depression without regulatory approval. The meta-analytic evidence suggests only small effects that are not robust across sensitivity analyses, with most individual trials being negative. If used off-label, it must be combined with mood stabilizers (preferably lamotrigine over lithium based on available data) and patients should be informed of the limited and conflicting evidence base 1, 3.

Related Questions

What is the evidence‑based information on transcranial magnetic stimulation (TMS) for bipolar II disorder?
What are the potential adverse effects and administration protocols of Transcranial Magnetic Stimulation (TMS)?
Is bladder surgery performed one month ago a contraindication to deep transcranial magnetic stimulation (deep TMS)?
Can a patient who recently had a large abdominal surgery and has a history of major depressive disorder safely begin transcranial magnetic stimulation (TMS) now?
What is the recommended treatment for bacterial sinusitis, including first-line antibiotics and supportive measures?
Are the prescribed laboratory tests for a potential research study participant considered non‑clinical safety (NCS) specimens?
In a 61-year-old male with end-stage renal disease on hemodialysis, a history of paroxysmal atrial fibrillation status post catheter ablation, currently in sinus rhythm with a resting heart rate of 62 bpm, off beta‑blocker, on chronic warfarin (with easy bruising) and amiodarone 200 mg daily, is cardioversion indicated?
How should a 31-year-old woman with recent abdominoplasty and prior treated cystitis, now presenting with low-back pain radiating to the pelvis, gross hematuria and foul‑smelling urine (without fever, trauma, vaginal discharge, incontinence, vomiting, or edema) be urgently evaluated and managed?
What is the recommended treatment plan for Lennox‑Gastaut syndrome?
How should I phrase a gastroenterology consult for a patient who received a red blood cell transfusion today and previously had a hematology‑directed transfusion trigger set at hemoglobin <8 g/dL (instead of the usual <7 g/dL)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.